SLC7A1在多发性骨髓瘤中的表达特征、 预后价值及潜在机制分析

Expression Characteristics, Prognostic Value, and Potential Mechanisms of SLC7A1 in Multiple Myeloma

摘要: 本研究旨在探讨SLC7A1在多发性骨髓瘤中的表达特征、预后价值及潜在机制。通过TIMER、GEO、Kaplan-Meier plotter等公共数据库分析SLC7A1的泛癌表达、MM中表达水平及其与患者总体生存期的关系，并结合临床样本进行验证，同时分析SLC7A1与患者临床特征的相关性。结果显示，SLC7A1在多种肿瘤中呈高表达趋势，在MM数据库及临床样本中均显著高表达；SLC7A1高表达患者总体生存期缩短，并与Scr、LDH、β2-微球蛋白水平升高及DS、ISS分期升高相关。功能富集分析显示，SLC7A1相关基因主要富集于氨基酸转运、精氨酸代谢、mTOR、HIF-1和AMPK等代谢相关通路。综上，SLC7A1可能与MM疾病进展和代谢相关通路改变有关，有望成为MM预后评估的潜在分子标志物。

Abstract: This study aimed to investigate the expression profile, prognostic value, and potential mechanisms of SLC7A1 in multiple myeloma (MM). Public databases, including TIMER, GEO, and Kaplan-Meier plotter, were used to analyze the pan-cancer expression of SLC7A1, its expression level in MM, and its association with overall survival. Clinical samples were further used for validation, and the correlation between SLC7A1 expression and clinicopathological characteristics was analyzed. The results showed that SLC7A1 tended to be highly expressed in multiple tumor types and was significantly upregulated in both MM database samples and clinical MM specimens. High SLC7A1 expression was associated with shorter overall survival, elevated Scr, LDH, and β2-microglobulin levels, as well as advanced DS and ISS stages. Functional enrichment analysis showed that SLC7A1-related genes were mainly enriched in metabolic pathways, including amino acid transport, arginine metabolism, mTOR, HIF-1, and AMPK signaling pathways. In conclusion, high SLC7A1 expression may be associated with MM progression and metabolic pathway alterations, and SLC7A1 may serve as a potential molecular biomarker for prognostic assessment in MM.